Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #FDA--Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio.

Business Wire • Feb 4, 2026

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Feb 2, 2026

Hologic (HOLX) International Revenue Performance Explored

Review Hologic's (HOLX) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks Investment Research • Feb 2, 2026

HOLX Stock Slips on Q1 Earnings and Revenue Miss, Margins Crash

Hologic slips after a Q1 EPS and revenue miss, as gross margin fell 150 bps with Diagnostics weakness offset by strong GYN Surgical growth.

Zacks Investment Research • Jan 30, 2026

Hologic Announces Financial Results for First Quarter of Fiscal 2026

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic Announces Financial Results for First Quarter of Fiscal 2026.

Business Wire • Jan 29, 2026

Hologic (HOLX) Misses Q1 Earnings and Revenue Estimates

Hologic (HOLX) came out with quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.03 per share a year ago.

Zacks Investment Research • Jan 29, 2026

Compared to Estimates, Hologic (HOLX) Q1 Earnings: A Look at Key Metrics

The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • Jan 30, 2026

Stay Ahead of the Game With Hologic (HOLX) Q1 Earnings: Wall Street's Insights on Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Hologic (HOLX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.

Zacks Investment Research • Jan 26, 2026

Hologic Q1 Earnings Preview: How Should You Play the Stock Now?

HOLX heads into Q1 earnings with rising EPS and revenue estimates, strong segment momentum and a pending buyout limiting near-term upside.

Zacks Investment Research • Jan 22, 2026

Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jan 22, 2026